A Phase II Clinical Trial of the Efficacy and Safety of Short-term (3 days) Enoxaparin for the Prevention of Venous Thromboembolism after Gastric Cancer Surgery by Kuroda, Shinji et al.
V enous thromboembolism (VTE) consists of pul-monary thromboembolism (PE) and deep vein 
thrombosis (DVT).  PE and DVT are divided into 
symptomatic and asymptomatic depending on the pres-
ence or absence of symptom.  VTE,  especially PE,  is 
one of the critical postoperative complications that can 
cause sudden death; therefore,  preventing VTE in the 
perioperative period is recognized as indispensable.  
Against this backdrop,  guidelines for VTE prevention 
were established in 2004 in Japan,  in which the risk 
for VTE is classiﬁed into 4 categories,  and a preven-
tion strategy is proposed for each category ［1］.  Most 
abdominal surgeries for cancer patients are included 
in the high-risk group,  for which either mechanical 
prophylaxis with intermittent pneumatic compression 
(IPC) or pharmacologic prophylaxis is recommended in 
this guideline.  Although prophylaxis with IPC has 
spread steadily across the country and reduced the 
incidence of perioperative VTE to some degree,  
around 20  (17.6 -23.7 ) of patients who underwent 
abdominal surgery were still diagnosed with DVT,  
from which lethal PE could result,  even with mechan-
ical prophylaxis by IPC in prospective clinical studies 
［2-4］.  In addition,  the mortality rate associated with 
perioperative PE has not decreased much since publi-
cation of the guideline ［5］.  Therefore,  pharmacologic 
prophylaxis has been increasingly considered neces-
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Although intermittent pneumatic compression (IPC) has become common as perioperative prophylaxis 
for venous thromboembolism (VTE) consisting of pulmonary thromboembolism (PE) and deep vein 
thrombosis (DVT),  the prophylactic eﬀect against VTE,  especially lethal PE,  is not yet satisfactory.  
Therefore,  pharmacologic prophylaxis,  such as with enoxaparin,  is desirable.  While the eﬃcacy and 
safety of enoxaparin have been proven in several clinical trials,  concern about bleeding with long-
term (at least 7 days) use have potentially decreased its widespread adoption.  We have launched a 
phase II study to evaluate the eﬃcacy and safety of short-term (3 days) enoxaparin,  in which a total of 
70 gastric cancer patients undergoing gastrectomy will be recruited,  and the primary endpoint is the 
incidence of DVT.  This study could contribute to making pharmacologic prophylaxis for VTE more 
common.
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sary for patients who undergo major abdominal sur-
gery unless they have active bleeding or a high bleed-
ing risk.
　 Detailed information about pharmacologic prophy-
laxis for VTE in cancer patients is described in the 
guideline from the American Society of Clinical 
Oncology (ASCO),  in which pharmacologic prophy-
laxis with unfractionated heparin (UFH) or low molec-
ular weight heparin (LMWH) such as enoxaparin for 
at least 7-10 days is recommended ［6］,  while no 
detailed information is provided in the Japanese guide-
line.  In the ENOXACAN study,  which was the ﬁrst 
randomized clinical trial comparing the prophylactic 
use of enoxaparin with UFH in cancer patients who 
underwent abdominal or pelvic surgery,  the frequency 
of VTE was lower in the enoxaparin group (14.7 ) 
than in the UFH group (18.2 ),  while there were no 
diﬀerences in bleeding events or other complications 
［7］.  In a meta-analysis comparing LMWH and UFH,  
LMWH seemed to be as eﬀective and safe as UHF 
［8］.  With the growing need for pharmacologic pro-
phylaxis for VTE in Japan,  a multicenter,  random-
ized,  clinical trial conducted in patients undergoing 
curative abdominal or pelvic cancer surgery showed 
that 14-day use of enoxaparin reduced the incidence 
of VTE to only 1.2  compared to 19.4  for IPC ［4］.
　 Despite these impressive results of LMWHs such 
as enoxaparin,  prophylactic use of LMWH still 
remains uncommon in abdominal surgery in Japan due 
to concerns about postoperative bleeding.  In addition,  
if enoxaparin is used for at least 7 days after surgery 
as recommended in the ASCO guideline,  an abdominal 
drain or an epidural catheter for pain control needs to 
be removed during enoxaparin use,  which could 
increase the risk of bleeding-related complications 
caused by removal of a drain or an epidural catheter.  
If short-term (3 days) use of enoxaparin is as eﬀective 
and safe as regular use,  this method allows us to 
remove an abdominal drain and an epidural catheter 
after the completion of enoxaparin use,  which can 
contribute to reducing the risk for bleeding-related 
complications and making our postoperative manage-
ment easier compared to regular use of enoxaparin.
　Thus,  we have launched a single-arm,  prospective,  
non-randomized,  non-comparative,  open label,  sin-
gle-center phase II clinical study to evaluate the eﬃ-
cacy and safety of short-term (3 days) use of enoxapa-
rin after surgery to prevent VTE in gastric cancer 
patients who undergo curative gastrectomy.  Fig.  1 
shows an overview of the study design.  This study is 
being conducted in compliance with the principles of 
the Declaration of Helsinki,  and this protocol has been 
approved by the institutional review board of Okayama 
University (No. 1512-002).  The UMIN registration 
number of this study is 000020235.
Endpoints
　 The primary endpoint is the incidence of DVT,  
which is basically examined with ultrasonography of 
the lower limbs between postoperative day (POD) 8 
and POD 14 and diagnosed by a cardiovascular physi-
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Fig. 1　 Overview of the study design IPC, intermittent pneumatic compression.
cian not involved in this study.  If systemic examina-
tion is judged necessary for the diagnosis of VTE,  
especially PE,  contrast-enhanced computed tomogra-
phy is alternatively permitted as a diagnostic modality 
for DVT,  which is diagnosed in this case by a radiol-
ogist not involved in this study.
　 The secondary endpoint is the incidence of bleed-
ing-related adverse events,  which are classiﬁed into 2 
groups,  major and minor bleeding events,  according 
to the criteria reported previously ［4］.  Safety is also 
evaluated based on the incidence of adverse events not 
related to bleeding.  
　 All patients will be followed-up until a regular 
checkup at approximately 1 month after surgery.  All 
adverse events are recorded according to the Clavien-
Dindo classiﬁcation (ver.  2.0) ［9］.  Information about 
each patientʼs background,  surgery,  pathology,  and 
pre- and post-operative laboratory data is also to be 
obtained from the medical record.
Eligibility Criteria
　 All patients who meet the eligibility criteria based 
on the inclusion and exclusion criteria will be invited 
for screening.  The main inclusion and exclusion crite-
ria are listed in Table 1.  Written,  informed consent 
must be obtained from the patient by an investigator 
before intervention.  Patients who do not participate 
in this study have VTE prophylaxis based on the 
guideline.
Treatment Methods
　 After written,  informed consent is obtained preop-
eratively,  prophylaxis for VTE is performed with 2 
methods of IPC and enoxaparin in the perioperative 
period.  Use of IPC starts during operation and con-
tinues until patients are able to walk adequately after 
surgery.  Enoxaparin (20 mg,  2,000 units) is subcuta-
neously injected twice a day for 3 days,  starting 36 h 
after surgery (in the evening of POD 1) and continues 
until the morning of POD 4.  Delay of initiation of 
enoxaparin due to concern over bleeding-related com-
plications is permitted at a physicianʼs discretion;  
however,  enoxaparin is injected 6 times in total until 
POD 7 in principle.  Enoxaparin is used once a day 
for 3 days for patients with creatinine clearance of 
30-50 ml/min.  An abdominal drain and an epidural 
catheter are removed more than 10-12 h after the ﬁnal 
injection of enoxaparin.
Statistical Consideration
　 The estimated incidence of VTE with mechanical 
prophylaxis with IPC is approximately 18  based on 
the incidence in two phase III clinical studies con-
ducted in Japanese cancer patients undergoing abdom-
inal surgery ［3,4］.  From the result in total hip or 
knee replacement patients showing a 50  reduction in 
the VTE risk of Japanese patients who were treated 
by at least 7 days use of enoxaparin ［10］,  the esti-
mated risk of VTE would be 9  with at least 7 days 
use of enoxaparin.  When 3 days of enoxaparin is 
assumed to have a similar prophylactic eﬀect as at 
least 7 days,  the estimated risk of VTE with 3 days 
of enoxaparin would also be 9 .
　 At the ﬁrst stage,  62 evaluable patients are 
required based on an estimated incidence of 9  and an 
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Table 1　 Patient eligibility
Inclusion criteria
Aged 40 years or older
Histologically diagnosed with gastric cancer
Written, informed consent
Exclusion criteria
History of venous thromboembolism
History of allergic reaction to heparin or heparinoid (including LMWH)
Active bleeding (except for bleeding from gastric cancer planned to be resected)
Acute bacterial endocarditis
Serious renal disorder (Ccr＜30 ml/min)
History of heparin-induced thrombocytopenia
Otherwise judged by the investigator as unsuitable for enrollment
LMWH, low molecular weight heparin; Ccr, creatinine clearance.
upper limit of incidence of 20  with alpha of 0.05 and 
beta of 0.2 according to Simonʼs two-stage design ［11］.  
If 8 or fewer incidences are observed among these 
ﬁrst stage patients,  an additional 4 patients will be 
entered.  At the time of ﬁnal analysis,  less than 8 
incidences among 66 patients will indicate that enoxa-
parin for 3 days merits further investigation.  A total 
of 70 patients is planned to be recruited in this study 
taking into account some unevaluable patients.  An 
interim analysis is planned after the ﬁrst 31 patients,  
half of the patients in the ﬁrst stage,  for reconsider-
ation of sample size.
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